Overview

Sildenafil Exercise: Role of PDE5 Inhibition

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

Exercise intolerance is an understudied phenomenon in people with CF. The investigators hypothesized that vascular dysfunction plays a significant role, and can be partially reversed by administration of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

National Jewish Health

Collaborators:

Augusta University
Cystic Fibrosis Foundation

Treatments:

Sildenafil Citrate